Term
Lovastatin
and other "statin"s |
|
Definition
CH 35 Agents Used in Dyslipidemia
|
Competitive inhibitors of HMG-CoA reductase (1st committed step in sterol synthesis)
↑ LDL receptors = ↑ LDL catabolism and liver’s extraction of LDL precursors (VLDL) from the blood = ↓ plasma LDL
|
Myositis, rhabdomyolysis
Hepatic toxicity (malaise,
anorexia, decreases in LDL)due to ↑ of aminotransferase activity
|
Atherosclerosis vascular disease, acute coronary syndromes
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
|
Inhibits VLDL secretion, in turn ↓ LDL production. ↑ VLDL clearance via the LDL pathway reduces triglycerides.
↓ HDL catabolism (= ↑HDL).
↓ lipoprotein(a)
|
Gastric irritation, cutaneous flushing, low incidence of hepatic toxicity, may ↓ glucose tolerance
|
Low HDL, elevated VLDL, LDL, Lp(a)
Rx: hypercholesterolemia
(normalizes LDL), severe
mixed lipemia
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
Fibrates
|
Agonist for peroxisome proliferator-activated receptor-alpha (PPAR-α) = ↑ transcription of lipoprotein lipase (LPL)
↓VLDL secretion, , ↑HDL
↑ oxidation of fatty acids
|
Myopathy, hepatic dysfunction
Gallstones due to ↑ in cholesterol content of bile
|
Hypertriglyceridemia, low HDL
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
Fibrates
|
Agonist for peroxisome proliferator-activated receptor-alpha (PPAR-α) = ↑ transcription of lipoprotein lipase (LPL)
↓VLDL secretion, , ↑HDL
↑ oxidation of fatty acids
|
Myopathy, hepatic dysfunction
Gallstones due to ↑ in cholesterol content of bile
|
Hypertriglyceridemia, low HDL
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
|
Binds to bile acids in the gut preventing reabsorption. ↑ Bile acid excretion => ↑ cholesterol conversion to bile acids.
Upregulates LDL receptors. ↑LDL & IDL uptake from plasma.
|
Constipation/bloating, steatorrhea,
malabsorption (vitamin K, folic
acid, charged drugs)
|
Elevated LDL, digitalis toxicity, pruritis
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
|
Binds to bile acids in the gut preventing reabsorption. ↑ Bile acid excretion => ↑ cholesterol conversion to bile acids.
Upregulates LDL receptors. ↑LDL & IDL uptake from plasma.
|
Constipation/bloating, steatorrhea,
malabsorption (vitamin K, folic
acid, charged drugs)
|
Elevated LDL, digitalis toxicity, pruritis
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
|
Selective inhibitor of intestinal absorption of cholesterol and phytosterols. Blocks sterol transporter NPC1L1 in intestine brush border inhibiting reabsorption of cholesterol excreted in bile
|
Low incidence of hepatic dysfunction, myositis
|
Elevated LDL, phytosterolemia
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
Dietary Aids
|
Inhibits cholesterol (re)absorption
|
Malabsorption of fat-soluble
vitamins
|
Rx: ↑ LDL, ↑ cholesterol
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
Dietary Aids
|
inhibits gastric and pancreatic lipases => triglycerides are not hydrolyzed into absorbable free FAs, and are excreted undigested
|
Malabsorption of fat-soluble
vitamins, steatorrhea, flatulence
|
Rx: weight loss
|
|
|
|
Term
|
Definition
CH 35 Agents Used in Dyslipidemia
Dietary Aids
|
Indigestible fat substitute in food
8 FA chains attached to sucrose
|
Malabsorption of fat-soluble
vitamins, diarrhea
|
Lower or eliminate fat content of high-fat foods
|
|
|
|